Moran Wealth Management, LLC Vertex Pharmaceuticals Inc Transaction History

Moran Wealth Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 23, 2025	SELL	$402.49 - $513.76 $11.8 Million - $15.1 Million	-29,300 Reduced 97.85%	644 $312,000
Q4 2024 Feb 07, 2025	BUY	$396.64 - $516.74 $343,490 - $447,496	866 Added 2.98%	29,944 $12.1 Million
Q3 2024 Nov 08, 2024	BUY	$460.0 - $505.78 $211,140 - $232,153	459 Added 1.6%	29,078 $13.5 Million
Q2 2024 Aug 13, 2024	BUY	$392.81 - $485.53 $500,439 - $618,565	1,274 Added 4.66%	28,619 $13.4 Million
Q1 2024 May 15, 2024	BUY	$407.69 - $446.08 $178,568 - $195,383	438 Added 1.63%	27,345 $11.4 Million

Q4 2023 Feb 07, 2024	BUY	$343.0 - $410.68 $672,966 - $805,754	1,962 Added 7.87%	26,907 $10.9 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $319,580 - $342,524	945 Added 3.94%	24,945 $8.67 Million
Q2 2023 Aug 10, 2023	SELL	$314.42 - $351.91 $139,916 - $156,599	-445 Reduced 1.82%	24,000 $8.45 Million
Q1 2023 May 10, 2023	BUY	$283.23 - $323.1 $2.55 Million - $2.91 Million	9,015 Added 58.43%	24,445 $7.7 Million
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $4.41 Million - $4.96 Million	15,430 New	15,430 $0

1,786

231M

1.83M

1.21M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $111B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Moran Wealth Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Moran Wealth Management, LLC with notifications on news.